Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.

Fiche publication

Date publication

juin 2026

Journal

BMJ open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi

Tous les auteurs :
Meskauskas A, Cohen R, Vernerey D, Bachet JB, Lacroix L, Laurent-Puig P, Paye F, Di Fiore F, Boige V, Garcia-Larnicol ML, Evrard C, Goumard C, Gelli M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42379715

Résumé

Curative-intent resection of colorectal cancer (CRC) liver metastasis (CRLM), combined with perioperative chemotherapy, is the standard of treatment for selected patients. However, accurately predicting which patients will benefit from this strategy remains challenging. Circulating tumour DNA (ctDNA) has emerged as a promising non-invasive biomarker for detecting minimal residual disease and predicting prognosis. This study aims to evaluate the prognostic value of ctDNA in patients with CRC undergoing surgery for CRLM.